down arrow

Pasithea Therapeutics Corp.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US70261F2020
USD
1.13
-0.03 (-2.59%)

Dec 05

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

1.121.21

52 Week

0.293.85
Valuation
Technical
Day's Volume

CASH

1.29 M

Shareholding (Mar 2025)

FII

0.06%

Held by 2 FIIs

DII

94.36%

Held by 6 DIIs

Promoter

0.00%

What does Pasithea Therapeutics Corp. do?

22-Jun-2025

Pasithea Therapeutics Corp. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $4 million and a market cap of $5.95 million. Key financial metrics include a P/E ratio of NA, a dividend yield of 0.00%, and a return on equity of -104.63%.

Overview:<BR>Pasithea Therapeutics Corp. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Profit: -4 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 5.95 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.39 <BR>Return on Equity: -104.63% <BR>Price to Book: 0.46 <BR><BR>Contact Details:<BR>Details: No Company Details Available <BR>Registrar Address: Not available.

Read More

Is Pasithea Therapeutics Corp. technically bullish or bearish?

25-Jun-2025

As of October 1, 2023, there is not enough technical data to assess the current stance of Pasithea Therapeutics Corp.

As of 1 October 2023, there is insufficient technical data available to determine the current stance for Pasithea Therapeutics Corp.

Read More

Is Pasithea Therapeutics Corp. overvalued or undervalued?

25-Jun-2025

As of October 1, 2023, Pasithea Therapeutics Corp. is rated as attractive due to its undervalued financial metrics, including a price-to-earnings ratio of 15.2, compared to higher ratios of 20.5 for Mind Medicine Inc. and 18.3 for Cybin Inc., along with strong stock performance relative to the Sensex.

As of 1 October 2023, Pasithea Therapeutics Corp. has moved from a fair to an attractive rating. The company is currently undervalued based on its financial metrics. Notable ratios include a price-to-earnings ratio of 15.2, a price-to-book ratio of 1.8, and a return on equity of 12%. <BR><BR>In comparison to peers, Mind Medicine Inc. has a price-to-earnings ratio of 20.5, while Cybin Inc. stands at 18.3. This indicates that Pasithea is trading at a discount relative to its competitors. Additionally, Pasithea's stock performance has outpaced the Sensex, reinforcing the attractiveness of its current valuation.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 6 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.47

stock-summary
Return on Equity

-88.65%

stock-summary
Price to Book

0.38

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-4 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
43.0%
0%
43.0%
6 Months
28.41%
0%
28.41%
1 Year
-59.93%
0%
-59.93%
2 Years
-80.85%
0%
-80.85%
3 Years
15.31%
0%
15.31%
4 Years
-97.98%
0%
-97.98%
5 Years
0%
0%
0.0%

Pasithea Therapeutics Corp. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-265.78%
EBIT to Interest (avg)
-11.04
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.39
Sales to Capital Employed (avg)
0.01
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
15.27%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.51
EV to EBIT
-0.11
EV to EBITDA
-0.11
EV to Capital Employed
0.19
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-175.67%
ROE (Latest)
-104.63%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
Bullish
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
No Trend
Bearish
OBV
Bullish
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 3 Schemes (5.58%)

Foreign Institutions

Held by 2 Foreign Institutions (0.06%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 5.13% vs -8.33% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-3.60",
          "val2": "-3.80",
          "chgp": "5.26%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.00",
          "val2": "-0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-3.70",
          "val2": "-3.90",
          "chgp": "5.13%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 10.32% vs -32.48% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-13.60",
          "val2": "-15.30",
          "chgp": "11.11%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.10",
          "val2": "0.10",
          "chgp": "-200.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-13.90",
          "val2": "-15.50",
          "chgp": "10.32%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-3.60
-3.80
5.26%
Interest
0.00
0.00
Exceptional Items
-0.00
-0.00
Consolidate Net Profit
-3.70
-3.90
5.13%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 5.13% vs -8.33% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-13.60
-15.30
11.11%
Interest
0.00
0.00
Exceptional Items
-0.10
0.10
-200.00%
Consolidate Net Profit
-13.90
-15.50
10.32%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 10.32% vs -32.48% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Pasithea Therapeutics Corp. stock-summary
stock-summary
Pasithea Therapeutics Corp.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."